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Abstract: African swine fever is a devastating hemorrhagic infectious disease, which affects domestic
and wild swines (Sus scrofa) of all breeds and ages, with a high lethality of up to 90–100% in
naïve animals. The causative agent, African swine fever virus (ASFV), is a large and complex
double-stranded DNA arbovirus which is currently spreading worldwide, with serious socioeconomic
consequences. There is no treatment or effective vaccine commercially available, and most of the
current research is focused on attenuated viral models, with limited success so far. Thus, new strategies
are under investigation. Extracellular vesicles (EVs) have proven to be a promising new vaccination
platform for veterinary diseases in situations in which conventional approaches have not been
completely successful. Here, serum extracellular vesicles from infected pigs using two different ASFV
viruses (OURT 88/3 and Benin ∆MGF), corresponding to a naturally attenuated virus and a deletion
mutant, respectively, were characterized in order to determine possible differences in the content of
swine and viral proteins in EV-enriched fractions. Firstly, EVs were characterized by their CD5, CD63,
CD81 and CD163 surface expression. Secondly, ASFV proteins were detected on the surface of EVs
from ASFV-infected pig serum. Finally, proteomic analysis revealed few specific proteins from ASFV
in the EVs, but 942 swine proteins were detected in all EV preparations (negative controls, and OURT
88/3 and Benin ∆MGF-infected preparations). However, in samples from OURT 88/3-infected animals,
only a small number of proteins were differentially identified compared to control uninfected animals.
Fifty-six swine proteins (Group Benin) and seven proteins (Group OURT 88/3) were differentially
detected on EVs when compared to the EV control group. Most of these were related to coagulation
cascades. The results presented here could contribute to a better understanding of ASFV pathogenesis
and immune/protective responses in the host.
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1. Introduction
Currently, African swine fever (ASF) constitutes the biggest threat faced by the world pork industry.
The causative agent, African swine fever (ASFV), is a large and complex double-stranded DNA virus
belonging to the Asfarviridae family [1]. ASFV affects domestic pigs and wild boars as well as other
African suids. Clinical signs during infection vary considerably from acute forms, with mortality rates
up to 90–100% in domestic pigs and wild boar to inapparent infections in bushpigs (Potamochoerus sp.)
and warthogs (Phacochoerus sp.). The latter are involved in the sylvatic cycle with a soft tick vector
Ornithodoros sp. [2]. The mature viral particle has an icosahedral morphology with a size range of
180–200 nm in diameter and is composed of multiple layers (nucleoprotein core, core shell, inner
envelope, viral capsid and external envelope when the virus egresses from the cell) [3]. The genome is
a double-stranded DNA molecule located in the nucleoprotein core, with approximately 170 to 193 kbp
codifying for 151 to 167 open reading frames (ORFs). Most differences in genome size are associated
with the gain or loss of members of multigene families (MGF) [4,5]. Mature viral particles infect
primarily monocytic/macrophages by clathrin-mediated endocytosis or macropinocytosis, and egress
is completed by the transport of mature viral particles by the microtubule network and finally budding
from the plasma membrane [6,7]
In 2007, ASFV was reintroduced to Europe after eradication in the mid-1990s from Spain and
Portugal, although the disease remained in Sardinia [8]. ASF-positive wild boar in Belgium and
Eastern Europe represent a significant reservoir that may hinder eradication [9,10]. The seriousness
of the ASF threat is exemplified by the first cases of ASFV in August 2018 in the world’s largest pig
producer, China [11]; the disease has now spread to all mainland Chinese provinces and reached
Vietnam, Cambodia, Laos and North Korea in 2019. Thus, the development of control and vaccination
strategies to prevent ASF has become even more important [12–14].
Developing a safe and effective DIVA (differentiate infected from vaccinated animals) vaccine
against ASFV is currently one of the main issues in animal health. Several attempts have been made
to develop a vaccine for ASFV using inactivated vaccines, subunit approaches and live attenuated
viruses, including gene deleted viruses [15] ranging from partial to some protection with some safety
concerns [16–18]. One example is the non-virulent, non-hemadsorbing Portuguese isolate OURT 88/3
which belongs to the genotype I [19]. When combined with a boost of a closely related hemadsorbing
Portuguese isolate (OURT 88/1), it can induce homologous and heterologous protection from 60 to
100% with almost no clinical signs or detectable viremia [17]. Another attenuated strain is the deletion
mutant Benin ∆MGF, which was derived from the wild-type virulent genotype I isolate Benin97/1 by
the deletion or interruption of several genes that inhibit the type I IFN response (MGF360-10L, 11L, 12L,
13L, 14L and MGF530/505-1R, 2R and 3R and MGF360-9L and MGF530/505-4R). This deletion mutant
is capable of inducing homologous protection against the parental isolate; however, clinical signs are
observed, and viremia is detected in infected pigs [20]. Nevertheless, several biosafety problems could
arise when immunization with attenuated viral strains is translated to the field. Therefore, research
into new DIVA “virus-free strategies” for vaccination is a priority in the field [16].
On the other hand, extracellular vesicles (EVs) have proven to be a promising new vaccination
platform for veterinary diseases in situations in which conventional approaches have not been
completely successful, such as PRRSV [21–24]. EVs are small, round vesicles of 50–400 nm in diameter
which are secreted by different cell types, and they are classified as microvesicles if formed by the
direct budding of the plasma membrane or exosomes if derived from late endosome trafficking and
multivesicular body formation before final release to the extracellular space [25,26]. Importantly,
exosome-like vesicles share the same pathway of formation as some viruses within multivesicular
bodies and viral factories, whereby viruses send proteins and nucleic acids to the extracellular space,
which later on can trigger immune responses against or in favor of viral replication [27–29].
EVs have been implicated in different biological processes, such as spreading viral infection or
modulating immune responses in the host by means of exploiting EV formation pathways to include
viral proteins, causing the activation of cellular and antibody-mediated immune pathways [27,29,30].
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One example is the VP40 of Ebola virus, which can induce apoptosis in the recipient cells and is more
effective in monocytes treated with EVs with a higher content of VP40 [31,32]. In contrast, during dengue
virus infection, there is a high production of EVs containing IFN-inducible transmembrane proteins 1,
2 and 3, which activates an antiviral state in different cells and contributes to the IFN-induced inhibition
of viral replication [33]. EVs produced during other viral infections such HIV-1 have ambiguous roles
depending of the type of EVs and the cell type producing those vesicles; for example, EVs released by
CD4+ T cells mediate the CD4-dependent inhibition of HIV-1 infection in vitro. On the other hand,
a large proportion of EVs released by HIV-1-infected cells contain gp120 protein, which is supposed to
play an important role by increasing viral infectivity in human lymphoid tissue [28]. Finally, EVs could
play a protective role in avoiding the interaction between viral particles and extracellular molecules,
such as by neutralizing antibodies. New evidence has also suggested that viruses (noroviruses and
rotaviruses) form clusters that are included into vesicles, generating a more infectious unit containing
more than one infectious particle that can resist the extracellular environment [34].
Given the role of extracellular vesicles in inducing immunological responses in different organisms
and the context of diseases, together with the fact that there is a search for new vaccine approaches
for ASFV, the main objective of this work was to characterize extracellular vesicles from serum from
ASFV-infected animals. Following this line of thought, two different ASFV viruses (OURT 88/3 and
Benin ∆MGF) were chosen when pigs survived infection for a sampling period. These correspond to a
naturally attenuated virus and a deletion mutant, respectively. This experimental procedure allowed
us to determine possible differences in swine and viral protein content on EV-enriched fractions that
could contribute to the better understanding of ASFV pathogenesis and immune/protective responses
in the host.
2. Materials and Methods
2.1. Cells and Viruses
Both the low-virulence non-hemabsorbing genotype I ASFV isolate OURT88/3 and attenuated
deletion mutant Benin ∆MGF, obtained from virulent genotype I isolate Benin97/1, were grown in
primary macrophage cultures derived from bone marrow. The preparation of viruses and virus titration
was carried out as previously reported [19,20,35]. Results are presented as the amount of virus infecting
50% of the macrophage cultures (TCID50/mL).
2.2. Experimental Design, Sampling, Clinical Evaluation and Viremia
Experiments were conducted in SAPO4 high containment facilities at The Pirbright Institute and
regulated by the Animals (Scientific Procedures) Act UK 1986 (Project License 70/8852, 05/04/2016).
Samples were taken from a larger experiment from day 0 to day 24 following the 3R concept for
minimizing animal use. Large White and Landrace crossbred female pigs, of 9 to 10 weeks old
(21–25 kg), from a high health status herd were used. Pigs were separated into two groups of six pigs
each. In group A (pigs A1 to A6), animals were immunized by the intramuscular route (IM) in the
neck muscles with 1 mL containing 104 TCID50/mL of OURT88/3 isolate, whereas in group B (pigs
B1 to B6), animals were immunized using the same route and dose with the deletion mutant Benin
∆MGF. The immunization day was defined as day 0 (0 dpi). EDTA blood and serum samples from the
jugular vein were collected from all pigs at day 7 and 24 pi. Rectal temperatures and clinical signs
were monitored daily as described [17]. DNA was extracted from blood samples taken at days 7 and
24 post infection and analyzed for ASFV genome detection by quantitative PCR (qPCR) [36].
2.3. Extracellular Vesicle Isolation: Size-Exclusion Chromatography
The isolation of serum-derived EVs by size exclusion chromatography (SEC) was performed as
previously described with swine sera samples from 7 dpi and 24 dpi [21]. Briefly, Sepharose CL-2B
(Sigma-Aldrich, St. Louis, MO, USA) was packed in 10 mL syringes to a final volume of 10 mL
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and equilibrated with PBS-citrate 0.32% (w/v). Frozen serum samples were thawed, centrifuged at
500× g for 10 min at room temperature to remove cellular debris, and 2 mL aliquots were loaded to
each column. The collection of 20 fractions of 0.5 mL each started immediately, using PBS-citrate
as the elution buffer. The protein content of each fraction was analyzed using a Bradford protein
quantification assay according to the manufacturer’s instructions (Pierce BCA protein quantification
assay kit, Thermo-Fisher, Waltham, MA, USA).
2.4. Flow Cytometry Analysis of Molecular Markers Associated with Extracellular Vesicles
A bead-based assay for the detection of classical exosome markers, CD63 and CD81, and two new
markers (CD5 and CD163) was used with some modifications to allow the use of this protocol in a BSL-3
environment. Briefly, EV-enriched fractions were coupled with Aldehyde/Sulfate Latex Beads, 4% w/v,
at 4µm (Invitrogen, Carlsbad, CA, USA) and then blocked with PBS 1×/BSA 0.1% (Sigma-Aldrich)/NaN3
0.01% (Sigma-Aldrich). Fractions were incubated in microtest conical-bottom 96-well plates for 30 min
at 4 ◦C with anti-CD63 (Clone H5C6) and anti-CD81 (Clone JS-81) antibodies (BD Biosciences, San Jose,
CA, USA) at 1:100 dilution, anti-CD5 (clone PG114A, Kingfisher Biotech, St Paul, MN, USA) at 1:200 or
anti-CD163 (clone 2A10 gently given by Dr. Javier Dominguez). After washing, a 1:100 dilution of
secondary antibody anti-mouse FITC (Southern Biotech, Birmingham, AL, USA) was incubated for
30 min at 4 ◦C. After the removal of unbound secondary antibodies by centrifugation and washing
with PBS/BSA, beads were suspended with 4% paraformaldehyde for 30 min to inactivate any possible
contamination with ASFV particles. Then, the plate was centrifuged and beads resuspended in PBS
and analyzed by flow cytometry using MACSQuant Analyzer 10 equipment (Miltenyi Biotec, Bergisch
Gladbach, Germany). The median fluorescence intensity (MFI) and bead count data were obtained by
FlowJo vX for PC TreeStar analysis software for every sample-reading file.
2.5. Detection of Viral Proteins on the Surface of Extracellular Vesicles Using Bead-Based Assay
A bead-based assay for the detection of viral proteins was used to phenotypically identify size
exclusion chromatography fractions containing EVs and viral proteins [21]. Briefly, EV-enriched
fractions were coupled with aldehyde/sulfate latex beads, 4% w/v, 4 µm (Invitrogen) and then blocked
with PBS 1×/BSA 0.1% (Sigma-Aldrich)/NaN3 0.01% (Sigma-Aldrich). Fractions were incubated in
microtest round-bottom 96-well plates for 30 min at 4 ◦C with anti-p30, anti-p54 and anti-p72 antibodies
(The Pirbright Institute) [17,37,38] at 1:100 dilution. After washing, a 1:100 dilution of secondary
antibody anti-mouse-FITC (Southern Biotech) was incubated for 30 min at 4 ◦C. After the removal of
unbound secondary antibodies by centrifugation, beads were resuspended in 4% paraformaldehyde for
30 min to inactivate any possible contamination with ASFV particles. Then, samples were centrifuged
and beads resuspended in PBS and analyzed by flow cytometry using MACSQuant Analyzer 10
equipment (Miltenyi Biotec). The median fluorescence intensity (MFI) and bead count data were
obtained by FlowJo vX for PC TreeStar analysis software for every sample-reading file.
2.6. Transmission Electron Microscopy and Negative Staining
Ten microliters of each sample were placed on Formvar-coated, glow discharged copper grids for
one minute. After removing excess sample with filter paper, the grids were briefly placed on droplets
of distilled water and the excess removed. The grids were placed on droplets of 3% aqueous uranyl
acetate for one minute before excess staining was removed and the grids were allowed to dry. Samples
were imaged using a FEI T12 TEM at 100 kV with a Tietz F214 camera. For size distribution, all images
were evaluated using ImageJ software and plotted in size-range percentages.
2.7. Mass Spectrometry
Extracellular vesicle fractions from size exclusion chromatography were heat-inactivated at 65 ◦C
for 2 h to inactivate any ASFV and sent to the Biological Mass Spectrometry Facility of the University
of Sheffield. Liquid chromatography (nanoLCULTRA-EKSIGENT) followed by mass spectrometry
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(nanoLC-MS/MS) was performed on an LTQ Orbitrap Velos (Thermo Fisher). Briefly, samples were
reduced with 10 mM DTT (Dithiothreitol), alkylated with 55 mM iodoacetamide and precipitated by
10% TCA (trichloroacetic acid). After washing with acetone, 2 µL of 8 M urea was added and samples
were brought to a final concentration of 1.6 M urea. One microgram of trypsin (Sus scrofa) was added
and digestions were carried out overnight at 37 ◦C. The reaction was stopped with 1% formic acid.
The amount of sample submitted to mass spectrometry analyses was based on nanoparticle tracking
analysis (see below) and ranged from 9.8 × 107 to 3.9 × 108 particles/mL among all samples analyzed.
MS/MS was performed in the LTQ using the data-dependent dynamic exclusion of the top 20 most
intense peptides using a repeat count of 1, a repeat duration of 30 s, an exclusion list size of 500 and
exclusion list duration of 30 s as parameters. The top 20 most intense peptides were isolated and
fragmented by low-energy CID at 35% collision energy.
2.8. Database Search and Protein Identification
Raw spectral data were investigated against a custom database compiled in FASTA format to
upload it into Maxquant 1.6. The databases were obtained from UniProtKB and contained complete
and partial sequences of ASFV (4125 sequences, 806 reviewed) and Sus scrofa (40,713 complete proteome
sequences). The sequences for the default contaminant database was also included in the search carried
out with Maxquant 1.6 software. Contaminants and proteins identified only by site modification were
filtered out from the list. Proteins found in all groups were scored positive if they had at least two
unique peptides and a 1% false discovery rate (FDR) for protein and peptide identification. In ASFV
protein analyses, the identification also included the criteria of being present on infected samples and
absent in control samples to avoid false identification hits due to the small number of proteins in the
ASFV UniprotKB database. ASFV proteins were evaluated only in terms of their presence/absence
while swine proteins were compared using a relative quantification approach.
2.9. Statistical Analysis
Pig protein hits were evaluated using Perseus v1.6. Contaminants, reversed identified hits and
those identified by site modification proteins were filtered out of the analysis. The matrix was reduced
by eliminating proteins identified with less than 1 unique peptide and 1% FDR. Then, sample groups
of controls and infected swine proteins identified in EV-enriched preparations were compared using a
two-sample Student’s t-test of the mean normalized intensity (LFQ) by the permutation-based FDR
method. Differentially expressed proteins were marked as significant if p < 0.05 (red) and p < 0.01
(volcano plot above threshold). After filtering, proteins of each group were compared in a Venn diagram
using Venny 2.1 [39] software to determine which proteins were unique and shared among groups.
2.10. Gene Ontology Analysis
Proteins found to be statistically significant by the Student’s t-test were evaluated for gene
ontology. For this, identified hits were examined using the Database for Annotation, Visualization
and Integrated Discovery (DAVID) v6.8 [40] to identify significant enrichment in terms of biological
processes, molecular functions and cellular components using the -log (p value) obtained previously,
and results were expressed in categories belonging to each enrichment term. Information about protein
interactions between significantly enriched proteins was retrieved by STRING software [41].
3. Results
3.1. Viremia and Clinical Signs of ASFV
As reported previously [42], OURT88/3-immunized pigs did not show changes in rectal
temperatures (Figure 1). However, except for pig B6, a transient increase in rectal temperature
above 40.5 ◦C for 1 or 3 days was observed in all pigs immunized with Benin ∆MGF between
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days 3 and 5 post immunization. Nevertheless, no other clinical signs were observed along with
increased temperatures.
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as viruses will mask the proteins associated with them. However, samples were checked at 14 and
24 dpi, and none of the pigs immunized with OURT88/3 (group A) showed detectable levels of virus
genome in blood, while in all pigs immunized with Benin ∆MGF (group B), moderate levels of ASFV
DNA were detected ranging from 2.85 × 104 to 1.45 × 105 copies at 14 dpi and 4.03 × 103 to 2 × 104
copies at 24 dpi [20]. As some EVs and viral particles have similar sizes, it was relevant to establish
whether ASFV was present in extracellular vesicle-enriched fractions to avoid false identifications of
viral proteins in further analyses. However, they could be used for the standardization and evaluation
of swine protein cargo on EV-enriched fractions.
3.2. Extracellular Vesicles in ASFV-Infected Sera
Both naïve (Figure 2a–c) and ASFV-infected (Figure 2d–f) sera at 7 dpi were used to obtain
EV-enriched fractions to standardize all the procedures. As described previously [21], swine EVs
eluted in fractions 7–10 from the exclusion chromatography column displayed CD163 and CD81 high
MFI values and exhibited a mean size distribution of 100–200 nm measured by TEM (Figure 2c,f).
Both naïve (Figure 2a–c) and ASFV-infected (Figure 2d–f) sera at 7 dpi were used to obtain EV-enriched
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strain used at 7 dpi (Figur 2f) which were absent in the negative control preparati ns, and further
identification is therefore needed. In addition, the presence of two new molecules was studied in our
EV fractions; CD5 was examined because it was previously present in the proteomic analyses for swine
enriched EV fractions [21]. Also, the presence of CD163 (scavenger receptor and soluble extracellular
form) was analyzed as it is a surface molecule related to macrophages and is thought to be involved in
the ASFV viral entry pathway [43]. Both molecular markers were present in EVs with higher levels
than those previously shown for swine EVs; therefore, they were selected for our further experiments.
In addition, there was no difference in the elution profile in terms of protein content and FACS staining
for the molecular markers, independently of the experimental group (uninfected or infected swine
serum from both groups) and the virus used.
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(b,e) size distribution as measured by electron microscopy; (c,f) transmission electron microscopy of
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On the other hand, samples from group B at 24 dpi (with detectable viremia) showed positive
MFI values, as observed in Figure 3c. This result was expected due to the presence of DNA, which was
suggestive of the presence of viral particles in the serum samples that could be captured in the assay.
As seen with OURT88/3, p72 is the viral protein with the highest MFI values of all three evaluated
proteins. Importantly, control samples (negative sera) showed MFI values for exosome markers but
not for viral proteins, confirming the specificity of antibodies used in this assay (Figure 3b).
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from a representative of uni fected swi e sera, (c) EV FACS profile from a representative animal
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3.4. Proteomic Analyses of ASFV-Infected Serum-Derived EVs
Protein composition in serum-derived EV fractions was analyzed in terms of ASFV viral proteins
and possible changes in pig proteins due to infection. Firstly, independent groups (Group A and Group
B) were compared with controls, and only viral proteins identified with 1% FDR and two or more
unique peptides and which were absent in controls were marked as positive identifications. As seen
in Tables 1 and 2, some viral proteins were identified in EV-enriched fractions, although only for the
Benin ∆MGF viral strain.
Table 1. Identified viral proteins in the OURT 88/3 group of porcine serum-derived EV-enriched
fractions at 24 days post infection. Columns correspond to each animal at different time points (Group
A, 7 and 24 dpi) where unique peptides were identified (red).
Identified Protein (by
Unique Peptides) and
Pig ID with Days Post
Infection
A1D7 A2D7 A1D24 A2D24 A4D24 A5D24 A6D24 CONTROL1
CONTROL
2
pL57L 0 1 0 0 0 0 0 0 0
ASFV_G_ACD_00330
(gene bank CBW46675.1) 0 1 0 0 0 0 0 0 0
VF602_ASFM2 Protein
B602L 0 0 1 0 0 0 0 0 0
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Table 2. Identified viral proteins in the Benin ∆MGF group of porcine serum-derived EV-enriched
fractions at 24 days post infection. Columns correspond to each animal at different time points (Group
B, 7 and 24 dpi) where unique peptides were identified (red).
Identified Protein (by Unique
Peptides) and Pig ID with Days
Post Infection
B1D7 B2D7 B1D24 B2D24 B3D24 B4D24 B5D24 B6D24 CONTROL1
CONTROL
2
gi|858945434|gb|AKO62698.1|
pJ328L 0 0 0 0 0 1 0 1 0 0
Structural protein p72 1 1 1 2 0 0 0 1 0 0
Hhypothetical protein
AFSV47Ss_0158 1 1 0 1 0 1 0 1 0 0
VF354_ASFWA Uncharacterized
protein B354L 0 1 1 0 1 0 0 0 0 0
In Group A (infected with OURT 88/3), there were no viral proteins identified by mass spectrometry
following the exclusion criteria applied to the analyses. Later, we reduced the exclusion criteria
(stringency of the analysis) in the detection after 1% FDR filtering without eliminating those proteins
with 1 unique peptide and evaluated those present in samples but not in controls. Following these
criteria, only 3 proteins were identified (pL57L, ASFV_G_ACD_330: gene bank CBW46675.1 and
VF602_ASFM2 protein B602L), two of which were in animals at 7 dpi and one in one animal at 24 dpi.
Although ASFV proteins were detected by FACS (bead-based assay, Figure 3), we were not able to
detect them by LC-MS/MS with the most stringent exclusion criteria.
In Group B (infected with Benin ∆MGF), EV-enriched fractions contained at least one protein
identified by LC-MS/MS following the exclusion criteria, but two more proteins were detected in this
preparation with less stringent analyses with 1 unique peptide and shared among samples. The best
hit of this analysis was for structural protein p72 (NP_042775.1), as shown in Table 2. As viral particles
were present in this group (detected by PCR), protein hits could be associated with viruses with
different size ranges of EVs. P72 represented the protein with the highest MFI in our FACS analyses for
EV-enriched fractions from sera of Group B (Figure 3), confirming the presence of this protein by two
different methods.
When swine proteins were evaluated, a total of 942 filtered swine proteins were identified by the
analysis of LFQ intensities, and some of them showed statistically significant differences in relative
expression (fold change) in a virus strain-dependent manner when compared with uninfected control.
Paired analyses were done between controls, groups and days post infection, showing no statistically
significant differences in Group A (OURT 88/3) at 7 dpi when compared to controls and samples at
24 dpi. It is important to notice that animals of Group A (OURT-88/3) had only seven proteins in
EV-enriched fractions with a significant fold change (p < 0.05), and from those, four were significant
at p < 0.01: coagulation factor VIII, C-X-C motif chemokine, complement C3 (LOC100517145) and
Ficolin-2 (Figure 4a and Table S1).
Nevertheless, in Group B (Benin ∆MGF), at 7 dpi, 20 proteins were detected as differentially
expressed when compared to controls (Table S2), as well as 56 proteins in EV-enriched fractions
(Figure 4b, p < 0.01) including HSP70, integrin beta, cAMP-dependent protein kinase, lymphocyte
antigen 6 complex, fibrinogen beta chain, different types of IgG, calcium-transporting ATPase,
coagulation factor VIII and a high quantity of uncharacterized pig proteins (Table S3). In addition,
when compared using a Venn diagram, all proteins identified as significant in EVs from Group A
(OURT 88/3) were also identified in EV preparations from Benin ∆MGF; however, there were 49
proteins identified as unique in Group B, representing 87.5% of all significant proteins from this group
(Figure 5).
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Figure 5. Venn diagram for the comparison of significantly expressed swine proteins in a virus-
dependent manner detected in serum-derived EVs.
Regarding EVs extracted from pigs infected with OURT88/3, there were not enough proteins
to perform further analyses as only four swine proteins were differentially expressed. However,
the situation for EVs from Benin ∆MGF-infected pigs was a different case, as 56 proteins from a
total of 942 proteins (selected with 1% FDR and two or more unique peptides) were differentially
expressed between controls and infected animals, at least in the extracellular vesicle-enriched fractions.
All significant proteins were further analyzed using gene ontology and string pathways to relate
expressed genes (Figure 6). The most enriched categories were threonine endopeptidase activities
(molecular functions), extracellular exosome and blood microparticles (cellular components) and
the integrin-mediated signaling pathway and platelet activation/aggregation (biological processes).
Using the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, the most enriched protein
pathways were related to coagulation cascade and platelet activation followed by those interactions in
the extracellular matrix (ECM) and focal adhesion.
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4. Discussion
In this study, we presented the first proteomic comparison of EV-enriched fractions obtained
from two different swine infections with attenuated strains of ASFV. Following previous experimental
work using swine sera [21], naïve and ASFV-infected pigs’ EV-enriched fractions were evaluated
with molecules reported to be present as a surface marker of swine EVs [21]. Interestingly, infection
with ASFV neither altered the elution profile nor the size distribution of extracellular vesicles within
enriched fractions 7 to 10 (Figure 2). Most of the vesicles measured were around 100–150 nm in
diameter, but in the case of the ASFV-infected group, small, round structures were observed in some
preparations (Figure 2F). We speculate that these could correspond to protein aggregates related to
infection which are not seen in all infected samples (viral capsid fragments or other structures related
to viral particles). Importantly, in naïve samples, those protein aggregates were not observed at all.
As ASFV infects macrophages, CD163 was included in our assays as a macrophage-related marker,
complemented by CD5, which is related to T-cells and B-cells. As expected, those membrane markers
allowed us to differentiate extracellular vesicle-enriched fractions independently of the virus used for
infection. Although these two molecules are associated with cell membranes such as lymphocytes and
macrophages, their expression after infections in extracellular vesicles derived from serum samples is
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variable. This is possibly associated with interactions with viral mechanisms. Interestingly, swine EVs
expressed CD163 in their membranes, as detected in the bead-based assay—a result that was considered
important due to the fact that CD163 was related to viral entry in ASFV [43]. However, recent work
using knockout pigs lacking CD163 challenged with ASFV Georgia2007/1 were not protected from
infection, demonstrating that CD163 is not crucial for viral entry, at least for this strain [44].
In our analyses of EV-enriched fractions, ASFV proteins were detected by bead-based assay
in both groups using antibodies against viral proteins p30, p54 and p72. However, MFI values
obtained in Group B preparations were higher than those in Group A. Those three proteins had been
reported as structural proteins of early (p30/p54) and late (p72) synthesis related to viral attachment,
viral internalization and capsid formation [4,45,46]. Extracellular vesicles have been reported to
contain viral proteins in some studies related to ASFV in the past, but without classifying them as
exosomes or extracellular vesicles [47–49]. In the particular case of p30, direct translocation through
the plasma membrane and the release of vesicles containing virally induced proteins (structural and
non-structural) has been proposed as a secretion mechanism for the extracellular transport of this
protein, although unknown mechanisms have not been ruled out [49]. Suggested pathways for protein
release mentioned in this work support the idea of a Golgi-independent pathway, as brefeldin treatment
does not inhibit p30 release to the culture media. However, vesicles are mentioned as an alternative
route for protein release, but it has been proved that exosome-like EV secretion is partially blocked by
brefeldin (quantified indirectly by the expression of CD81 in Western blot, CD63-GFP expression by
FACS and microRNA) [50].
Several viral proteins had been identified as potential vaccine targets and are capable of inducing
neutralizing antibodies including p30, p54 and p72 [16,51]. However, antibodies for those proteins are
not sufficient to protect pigs against viral replication in a challenge trial, as vaccination approaches
demonstrated only a delay in the appearance of clinical symptoms and reduced levels of viremia when
compared to the control group [52] but not sterilizing immunity.
Extracellular vesicles have been studied during viral infections, but nevertheless their role is
still controversial depending on each particular interaction between the virus and the host. In some
cases, viral proteins associated with these vesicles facilitate viral infectivity and impair the immune
response in the host. Also, vesicles are able to transfer the cell receptors necessary to infect cells that
were previously incapable of interacting with the virus [28,31,53–55]. On the other hand, it has been
reported that EVs from virus-infected cells, such as HSV-1, could induce the opposite effect and inhibit
viral infection by activating different immune mechanisms mediated by the delivery of viral antigens
on EVs to receptor cells [33,56]. Whether ASFV-derived vesicles have a role in pathogenesis or immune
response is yet to be examined.
Few viral proteins were identified by mass spectrometry in both EV preparations (Groups A
and B) and only p72 was selected by our exclusion criteria of two unique peptides. Nevertheless,
other viral proteins were detected in more than one animal, but with 1 unique peptide, making
those identifications potential candidates for further evaluation. We suspect that the small number
of proteins identified could be related to a lack of information regarding protein sequences for ASFV
virus. It is important to mention that the ASFV protein database available at UniprotKB has presently
4419 protein sequences—a small number compared with other viruses such as PRRSV (around 25,000
sequences) or influenza virus (788,906 sequences). Another limitation in protein identification is
associated directly with biosafety protocols for analyzing BSL-3/SAPO4 samples of ASFV. In our case,
EV-enriched fractions required heat inactivation at 60 ◦C for 2 h. This process could contribute to
protein degradation and loss of information within EV-enriched samples, because when evaluated
after EV isolation for viral proteins in the FACS bead-based assay, at least some samples gave positive
results in the assay using specific antibodies against those proteins. The different thresholds in each
technique could be related to this apparent discrepancy in protein detection when comparing both
sets of data. Taken together, these results indicate that EVs could be a source of new viral antigens
that could explain pathogenicity and immune response during infection with different viral strains,
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but methods for sample processing in BSL-3/SAPO4 containment need to be improved to increase
protein hits in the analysis.
In addition, it was necessary to evaluate swine proteins on EV cargo and determine whether
viral infection with different strains could modify the protein content of those EVs. Interestingly,
we identified 942 swine proteins in all EV preparations (controls, and OURT 88/3 and Benin
∆MGF-infected preparations); however, in OURT 88/3 swine sera, only a small number of proteins
were differentially expressed compared to controls. OURT 88/3 has been reported to be a low virulent
strain (naturally attenuated) with few to no clinical signs and no detectable/low intermittent viremia
post immunizations [20], and this low pathogenicity with almost no effect in the host could reflect the
few modifications of porcine protein expression detected in the EV-enriched fractions when compared
with control (non-infected) samples. Importantly, infections with this attenuated strain protect against
a lethal challenge from the same genotype I and even other genotypes [17,57]. In contrast, Benin ∆MGF
is a deletion mutant in which some genes of the multigene family (related to IFN expression) were
deleted. These genes were similar to but not the same as those absent in OUTR 88/3. Benin ∆MGF
has intact CD2v and EP153R genes as compared to OURT88/3. Animals infected with this mutant
exhibit detectable viremia and clinical signs post-infection, possibly associated to another feature of
this particular strain; despite the absent genes in both viruses [20], nevertheless, this mutant has been
characterized as an inducer of protection [42].
For all these reasons, we tentatively hypothesize that there was a relationship between the viral
proteins detected in the EV-enriched fractions we examined and the modifications in swine proteins
associated with those fractions of EVs (20 significant proteins at 7 dpi and 56 significant proteins
at 24 dpi), including those proteins identified as differentially expressed (seven proteins) in OURT
88/3 infections. Most of these proteins are related to threonine endopeptidase activities, integrin and
fibrinogen complexes and platelet activation and integrin-mediated signaling pathways. Previous
reports about proteomic analysis after infection have been performed using either Vero cells or in vivo
trials using gastro-hepatic lymph nodes exhibiting similar protein groups which were identified as over
or sub-expressed, such as proteasome-related proteins, heat shock proteins or immunoglobulins [58,59],
despite our focus on only extracellular vesicle-enriched fractions. Importantly, those results open
a new path to explore the interactions between host cells and the virus, including the modulation
of the immune system by different strategies including extracellular vesicles. For example, platelet
function abnormalities or thrombocytopenia have been related to unpredictable delivery hemorrhages
in inherited disorders in humans [60]. Also, fibrinogen is a serum multi-chain protein which, when
activated, aggregates to form fibrin, one of the main components of a blood clot [61]. On the other
hand, it has been shown that dengue virus nonstructural-1 protein (NS1) generates antibodies to
common epitopes on human blood clotting and integrin/adhesin proteins, with potential implications
in hemorrhagic fever pathogenesis being induced by this virus [62]. All in all, these findings suggested
some alterations in the coagulation system that could be associated with the virus–host cell interactions
involved in the pathogenesis of ASFV. Further investigations are required to sustain this hypothesis.
5. Concluding Remarks
In this study, we presented new evidence that different strains of ASFV modify one aspect of
host biology related to extracellular vesicles. Several viruses are able to exploit the EV formation
and secretion pathway in different ways to either interfere with immune responses [28,31] or block
viral entry and replication [33,56]. We think that exploring new aspects of ASFV infections such as
EV-enriched fraction content (viral and host proteins) will contribute to understanding how different
viral strains interact with host cells and modify the expression of immune response genes and proteins.
Recent research works have made contributions here by exploring the proteomics of the viral particles
and intracellular proteome of this virus [3,63]. Our work was focused on extracellular vesicle-enriched
fractions, as these have been shown to be important for several viral infections, and recently they have
been used as a vaccination strategy for another important swine disease—PRRS virus [22].
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As mentioned, ASFV is a complex virus that is causing major outbreaks in Europe and Asia [12,
13,64]. With no vaccine or treatment available for this pathogen, slaughter is the only effective
control measure [65]. Several genotypes [66] and immune-suppression genes [67], long-term viral
infections [68,69], gaps in knowledge in biology and immunology and several spreading vectors such as
wild boars and Ornithodoros spp. ticks [70–73] generate an urgent need to cover the less-explored aspects
of this virus to control or prevent pandemics that could affect the global economy in animal production.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/11/10/882/s1,
Table S1: swine proteins identified as differentially expressed at 24dpi in OURT 88/3 infected animals, Table S2:
swine proteins identified as differentially expressed at 7dpi in Benin ∆MGF infected animals, Table S3: swine
proteins identified as differentially expressed at 24dpi in Benin ∆MGF infected animals.
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